A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MDLN SEC filings page.
Medline (MDLN) reported $28.4B in revenue for fiscal year 2025, up 11.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue growth has translated into operating profit, but rising reinvestment and a thinner equity cushion are absorbing more of the cash.
From FY2024 to FY2025, operating cash flow fell1.4% while free cash flow fell8.3% , showing cash conversion weakened beyond operating performance. Capital expenditures consumed25.6% of operating cash flow in FY2025, up from20.0% in FY2024, so more internally generated cash was committed to reinvestment.
Gross-margin improvement was not linear: it rose 2.0 percentage points from FY2023 to FY2024, then fell 0.9 percentage points in FY2025. In FY2025, cost of revenue grew
Liabilities rose
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Medline's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Medline scores 63/100 on it among other operating companies.
Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Medline scores 66/100 on it among other operating companies.
Medline's net debt of $10.5B, being $12.5B of long-term debt less $1.9B of cash, came to 3.27 times its EBITDA in fiscal year 2025. Operating companies are ranked here on long-term debt less cash against their EBITDA, where a lower multiple is the safer one, and Medline scores 18/100 among other operating companies.
Medline held $4.29 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 4.29. Liquidity ranks operating companies on that ratio, and Medline scores 89/100 among other operating companies.
Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Medline scores 46/100 on it among other operating companies.
Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Medline scores 66/100 on it among other operating companies.
Medline scores 2.31, placing it in the grey zone between 1.81 and 2.99. The largest contribution to the score comes from a market capitalization of $51.9B against total liabilities of $27.7B. This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Medline passes 4 of 5 computable financial strength tests (4 of the nine could not be computed from available data). All 1 profitability signals pass (positive income, cash flow, and earnings quality), all 2 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
Medline earns $2.34 in operating income for every $1 of interest expense ($2.2B vs $945.0M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.
Key Financial Metrics
Earnings & Revenue
Medline generated $7.9B in revenue in Q3 2026. This represents an increase of 10.4% from the same quarter a year earlier. Against the prior quarter it is up 2.2%.
Medline's EBITDA was $759.0M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 8.2% from the same quarter a year earlier. Against the prior quarter it is up 16.6%.
Medline reported $195.0M in net income in Q3 2026. This represents a decrease of 38.7% from the same quarter a year earlier. Against the prior quarter it is up 225.0%.
Medline earned $0.22 per diluted share (EPS) in Q3 2026. Against the prior quarter it is up 214.3%.
Cash & Balance Sheet
Medline generated $884.0M in free cash flow in Q3 2026, representing cash available after capex. This represents an increase of 65.2% from the same quarter a year earlier. Against the prior quarter it is up 46.4%.
Medline held $2.3B in cash against $12.6B in long-term debt as of Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Medline's gross margin was 24.5% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 1.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.3 percentage points.
Medline's operating margin was 6.4% in Q3 2026, reflecting core business profitability. This is down 1.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.2 percentage points.
Medline's net profit margin was 2.5% in Q3 2026, showing the share of revenue converted to profit. This is down 2.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.7 percentage points.
Medline's quarterly ROE was 1.7% in Q3 2026: one quarter's net income over shareholder equity, not annualized. Against the prior quarter it is up 1.1 percentage points.
Capital Allocation
Medline repurchased no shares in Q3 2026. This represents a decrease of 100.0% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Medline invested $141.0M in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 39.6% from the same quarter a year earlier. Against the prior quarter it is up 27.0%.
Not reported for Q3 2026.
MDLN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.9B+10.4% | $7.7B+11.6% | $7.4B+10.7% | $7.8B | $7.1B | $6.9B | $6.6B | N/A |
| Cost of Revenue | $5.9B+13.2% | $5.5B+9.8% | $5.5B+14.3% | $5.9B | $5.2B | $5.0B | $4.8B | N/A |
| Gross Profit | $1.9B+2.7% | $2.2B+16.3% | $1.8B+0.9% | $1.9B | $1.9B | $1.9B | $1.8B | N/A |
| SG&A Expenses | $1.3B+12.8% | $1.3B+20.7% | $1.2B+14.8% | $1.3B | $1.1B | $1.1B | $1.1B | N/A |
| Operating Income | $500.0M-12.9% | $395.0M-38.5% | $422.0M-26.1% | $425.0M | $574.0M | $642.0M | $571.0M | N/A |
| EBITDA | $759.0M-8.2% | $651.0M-27.0% | $676.0M-17.4% | N/A | $827.0M | $892.0M | $818.0M | N/A |
| Interest Expense | $165.0M-33.5% | $168.0M-33.6% | $165.0M-32.4% | N/A | $248.0M | $253.0M | $244.0M | N/A |
| Income Tax | $68.0M+195.7% | $96.0M+269.2% | $52.0M+225.0% | $26.0M | $23.0M | $26.0M | $16.0M | N/A |
| Net Income | $195.0M-38.7% | $60.0M-81.8% | $129.0M-59.6% | N/A | $318.0M | $329.0M | $319.0M | N/A |
| EPS (Basic) | $0.23 | $0.07 | $0.16 | N/A | N/A | N/A | N/A | N/A |
| EPS (Diluted) | $0.22 | $0.07 | $0.16 | N/A | N/A | N/A | N/A | N/A |
| Diluted Shares (Avg) | 1.32B | 861M | 825M | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: R&D Expenses.
MDLN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $40.2B | $39.4B | $39.0B | $38.5B+7.0% | N/A | N/A | N/A | $36.0B |
| Current Assets | $12.7B | $11.7B | $11.2B | $10.7B+29.1% | N/A | N/A | N/A | $8.3B |
| Cash & Equivalents | $2.3B+143.0% | $2.3B+298.5% | $2.2B+166.2% | $1.9B+874.4% | $955.0M | $584.0M | $840.0M | $199.0M |
| Short-Term Investments | $1.3Bn/m | $350.0Mn/m | $0n/m | $0n/m | $0 | $0 | $0 | $0 |
| Inventory | $4.8B | $4.7B | $4.8B | $4.8B+7.0% | N/A | N/A | N/A | $4.5B |
| Accounts Receivable | $3.8B | $3.7B | $3.7B | $3.5B+9.8% | N/A | N/A | N/A | $3.2B |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0 | $0 | $0 | $0 |
| Goodwill | $8.1B | $8.1B | $8.1B | $8.1B+0.2% | N/A | N/A | N/A | $8.1B |
| Total Liabilities | $20.8B | $20.3B | $27.7B | $27.7B+42.6% | N/A | N/A | N/A | $19.5B |
| Current Liabilities | $3.1B | $2.7B | $2.5B | $2.5B+2.0% | N/A | N/A | N/A | $2.4B |
| Non-Current Liabilities | $17.7B | $17.6B | $17.1B | $16.7B-1.8% | N/A | N/A | N/A | $17.0B |
| Long-Term Debt | $12.6B | $12.5B | $12.5B | $12.5B-24.0% | N/A | N/A | N/A | $16.4B |
| Total Equity | $11.8B | $11.6B | $11.3B | $10.7B-35.0% | N/A | N/A | N/A | $16.5B |
| Retained Earnings | $377.0M | $182.0M | $122.0M | -$7.0M | N/A | N/A | N/A | N/A |
MDLN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.0B+61.2% | $715.0M+262.9% | $412.0M-39.6% | $229.0M | $636.0M | $197.0M | $682.0M | N/A |
| Depreciation & Amortization | $259.0M+2.4% | $256.0M+2.4% | $254.0M+2.8% | $261.0M | $253.0M | $250.0M | $247.0M | N/A |
| Stock-Based Compensation | $29.0M+93.3% | $29.0M+93.3% | $23.0M+21.1% | N/A | $15.0M | $15.0M | $19.0M | N/A |
| Capital Expenditures | $141.0M+39.6% | $111.0M+0.9% | $96.0M-2.0% | $138.0M | $101.0M | $110.0M | $98.0M | N/A |
| Free Cash Flow | $884.0M+65.2% | $604.0M+594.3% | $316.0M-45.9% | N/A | $535.0M | $87.0M | $584.0M | N/A |
| Investing Cash Flow | -$980.0Mn/m | -$461.0Mn/m | -$96.0Mn/m | -$138.0M | -$101.0M | -$143.0M | -$92.0M | N/A |
| Financing Cash Flow | -$48.0Mn/m | -$159.0Mn/m | -$13.0Mn/m | $897.0M | -$161.0M | -$328.0M | -$9.0M | N/A |
| Share Buybacks | $0-100.0% | $0-100.0% | $0-100.0% | $0 | $18.0M | $6.0M | $9.0M | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
MDLN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 24.5%-1.9pp | 28.8%+1.2pp | 25.0%-2.4pp | 24.6% | 26.4% | 27.7% | 27.5% | N/A |
| Operating Margin | 6.4%-1.7pp | 5.1%-4.2pp | 5.7%-2.9pp | 5.5% | 8.1% | 9.3% | 8.6% | N/A |
| Net Margin | 2.5%-2.0pp | 0.8%-4.0pp | 1.8%-3.0pp | N/A | 4.5% | 4.8% | 4.8% | N/A |
| Return on Equity | 1.7% | 0.5% | 1.1% | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 0.5% | 0.1% | 0.3% | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | 4.04 | 4.33 | 4.41 | 4.29+0.9x | N/A | N/A | N/A | 3.39 |
| Debt-to-Equity | 1.06 | 1.08 | 1.11 | 1.16+0.2x | N/A | N/A | N/A | 0.99 |
| Liabilities-to-Equity | 1.76 | 1.75 | 2.46 | 2.58+1.4x | N/A | N/A | N/A | 1.18 |
| Asset Turnover | 0.20 | 0.20 | 0.19 | 0.20 | N/A | N/A | N/A | N/A |
| FCF Margin | 11.3%+3.7pp | 7.9%+6.6pp | 4.3%-4.5pp | N/A | 7.5% | 1.3% | 8.8% | N/A |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Medline MDLN | FY2025 | $28.4B | N/A | N/A | $51.9B | 58/100 |
| Becton, Dickinson and Co. BDX | FY2025 | $21.8B | $1.7B | 7.7% | $59.4B | 51/100 |
| Alcon Inc. ALC | FY2025 | $10.4B | $980.0M | 9.4% | $35.6B | 64/100 |
| ResMed Inc. RMD | FY2026 | $5.7B | $1.5B | 26.9% | $33.7B | 86/100 |
| West Pharmaceutical Services, Inc. WST | FY2025 | $3.1B | $493.7M | 16.1% | $29.0B | 75/100 |
| Solventum Corporation SOLV | FY2025 | $8.3B | $1.6B | 18.7% | $15.1B | 50/100 |
Where Medline Ranks
Frequently Asked Questions
Medline (MDLN) reported $28.4B in total revenue for fiscal year 2025. This represents a 11.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Medline (MDLN) revenue grew by 11.5% year-over-year, from $25.5B to $28.4B in fiscal year 2025.
Medline (MDLN) had EBITDA of $3.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, Medline (MDLN) had $1.9B in cash and equivalents against $12.5B in long-term debt.
Medline (MDLN) had a gross margin of 26.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Medline (MDLN) had an operating margin of 7.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
Medline (MDLN) generated $1.3B in free cash flow during fiscal year 2025. This represents a -8.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Medline (MDLN) generated $1.7B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
Medline (MDLN) had $38.5B in total assets as of fiscal year 2025, including both current and long-term assets.
Medline (MDLN) invested $447.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Medline (MDLN) invested $80.0M in research and development during fiscal year 2025.
Medline (MDLN) had a current ratio of 4.29 as of fiscal year 2025, which is generally considered healthy.
Medline (MDLN) had a debt-to-equity ratio of 1.16 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Medline (MDLN) had a liabilities-to-equity ratio of 2.58 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Medline (MDLN) has no price-to-earnings ratio at the moment: no full year of net income reported yet. The market capitalization is $51.9B as of Nov 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Medline (MDLN) trades at 1.7x sales, its market capitalization divided by $30.7B revenue, trailing 12 months to September 26, 2026. The market capitalization is $51.9B as of Nov 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Medline (MDLN) has an Altman Z-Score of 2.31, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Medline (MDLN) has a Piotroski F-Score of 4 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Medline (MDLN) has an interest coverage ratio of 2.34x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
Medline (MDLN) scores 58 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.